Prognostic Impact of Negative Serum (1,3)-β-D-glucan in Patients With Candidemia

Daniele Roberto Giacobbe^{1

2}, Marco Berruti^{1

2}, Malgorzata Mikulska^{1

2}

Affiliations

¹ Dipartimento di Scienze della Salute, University of Genoa, Genoa, Italy.
² Clinica Malattie Infettive, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Policlinico San Martino, Genoa, Italy.

Comment

Daniele Roberto Giacobbe et al. Clin Infect Dis. 2020.

. 2020 Aug 14;71(4):1124-1126.

doi: 10.1093/cid/ciz1051.

Daniele Roberto Giacobbe^{1

2}, Marco Berruti^{1

2}, Malgorzata Mikulska^{1

2}

¹ Dipartimento di Scienze della Salute, University of Genoa, Genoa, Italy.
² Clinica Malattie Infettive, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Policlinico San Martino, Genoa, Italy.

No abstract available

Comment in

Reply to Giacobbe et al.
Agnelli C, Valerio M, Bouza E, Muñoz P. Agnelli C, et al. Clin Infect Dis. 2020 Aug 14;71(4):1126. doi: 10.1093/cid/ciz1055. Clin Infect Dis. 2020. PMID: 31665248 No abstract available.

Clinical Relevance and Prognostic Value of Persistently Negative (1,3)-β-D-Glucan in Adults With Candidemia: A 5-year Experience in a Tertiary Hospital.
Agnelli C, Bouza E, Del Carmen Martínez-Jiménez M, Navarro R, Valerio M, Machado M, Guinea J, Sánchez-Carrillo C, Alonso R, Muñoz P. Agnelli C, et al. Clin Infect Dis. 2020 Apr 15;70(9):1925-1932. doi: 10.1093/cid/ciz555. Clin Infect Dis. 2020. PMID: 31680136